FDA
-
-
-
-
-
-
-
Sorrento's (SRNE) Scilex to Acquire Ancora Medical
-
-
-
-
-
-
-
Sorrento's (SRNE) Scilex to Initiate Phase 2 Study of SP-103
-
-
-
-
-
-
-
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., to Present SP-102 (SEMDEXA™) Efficacy and Safety Data from its Pivotal Phase 3 Clinical Trial Program for Sciatica
-
-
-
-
-
-
-
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido® with preliminary gross sales of approximately $8.1 million during the
-
-
-
-
-
-
-
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.
-
-
329,943 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

